Low-risk prostate tumors reveal molecular signs linked to more aggressive cancer

A recent study has uncovered molecular indicators that may identify more aggressive prostate cancer in a subset of patients previously categorized as low risk, based on clinical assessment alone. This discovery, published in npj Digital Medicine by researchers at the KTH Royal Institute of Technology, could pave the way for innovative therapeutic approaches.

The researchers utilized a comprehensive multi-omics analysis—combining genomics, transcriptomics, and epigenomics—with machine learning and network analysis to reveal molecular traits of aggressive prostate cancer that are not evident through standard clinical risk classification. Assistant Professor Arian Lundberg, whose lab focuses on the tumor microbiome, emphasizes that integrating these molecular layers into a single patient-specific profile provides a more complete understanding of tumor biology.

The machine-learning model, developed by a team led by Assistant Professor Golnaz Taheri, was pivotal in identifying molecular features linked to rapid progression in tumors previously deemed low risk. This research, while still in its experimental phase, holds promise for more precise risk stratification and the identification of patients who might benefit from earlier or more targeted treatment.

Lundberg's team plans to validate these findings through laboratory experiments to determine their potential as diagnostic markers or therapeutic targets.